RTTR Ritter Pharmaceuticals Inc.

0.2
0  0%
Previous Close 0.2
Open 0.2
Price To Book -0.53
Market Cap 1,991,276
Shares 10,164,756
Volume 2,410,247
Short Ratio
Av. Daily Volume 3,763,379
Stock charts supplied by TradingView

NewsSee all news

  1. Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement

    Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen's Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Ritter

  2. Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update

    LOS ANGELES, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of therapeutic products that modulate the gut microbiome to treat

  3. Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives

    LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to

  4. Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

    LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data failed to meet primary endpoint - September 12, 2019.
RP-G28
Lactose intolerance

Latest News

  1. Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement

    Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen's Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Ritter

  2. Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update

    LOS ANGELES, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of therapeutic products that modulate the gut microbiome to treat

  3. Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives

    LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to

  4. Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

    LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to